Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.

@article{Hersey1991TreatmentOA,
  title={Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.},
  author={Peter Hersey and Gordon R. McLeod and Damien B. Thomson},
  journal={British journal of haematology},
  year={1991},
  volume={79 Suppl 1},
  pages={60-6}
}
The present studies were designed to examine whether treatment of disseminated melanoma with a combination of recombinant interferon alpha (rIFN alpha-2a) and DTIC may provide better results than either agent alone. Two dose levels of rIFN alpha-2a were examined with the same dose and schedule of DTIC administration. In the first study 76 patients were treated with rIFN alpha-2a (3 x 10(6) IU days 1-3, 9 x 10(6) IU days 4-70 then 9 x 10(6) IU TIW) plus DTIC (i.v. 200 mg/m2, escalating to 800 mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

Similar Papers

Loading similar papers…